Relmada Therapeutics Inc (RLMD) has a current Price-to-Book (P/B) ratio of 15.32. Compared to its 3-year average P/B ratio of 2.12, the current P/B ratio is approximately 623.28% higher. Relative to its 5-year average P/B ratio of 2.83, the current P/B ratio is about 441.64% higher. Relmada Therapeutics Inc (RLMD) has a Forward Free Cash Flow (FCF) yield of approximately -12.48%. Compared to its 3-year average FCF yield of -156.72%, the current FCF yield is approximately -92.04% lower. Relative to its 5-year average FCF yield of -101.95%, the current FCF yield is about -87.76% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RLMD competitors is 6.34, providing a benchmark for relative valuation. Relmada Therapeutics Inc Corp (RLMD.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RLMD increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RLMD in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RLMD currently overvalued or undervalued?

What is Relmada Therapeutics Inc (RLMD) fair value?

RLMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Relmada Therapeutics Inc (RLMD) is between NaN to NaN according to relative valuation method.

How does RLMD's valuation metrics compare to the industry average?

The average P/S ratio for RLMD's competitors is 6.34, providing a benchmark for relative valuation. Relmada Therapeutics Inc Corp (RLMD) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Relmada Therapeutics Inc (RLMD) as of Mar 03 2026?

As of Mar 03 2026, Relmada Therapeutics Inc (RLMD) has a P/B ratio of 15.32. This indicates that the market values RLMD at 15.32 times its book value.

What is the current FCF Yield for Relmada Therapeutics Inc (RLMD) as of Mar 03 2026?

As of Mar 03 2026, Relmada Therapeutics Inc (RLMD) has a FCF Yield of -12.48%. This means that for every dollar of Relmada Therapeutics Inc's market capitalization, the company generates -12.48 cents in free cash flow.

What is the current Forward P/E ratio for Relmada Therapeutics Inc (RLMD) as of Mar 03 2026?

As of Mar 03 2026, Relmada Therapeutics Inc (RLMD) has a Forward P/E ratio of -5.60. This means the market is willing to pay $-5.60 for every dollar of Relmada Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Relmada Therapeutics Inc (RLMD) as of Mar 03 2026?

As of Mar 03 2026, Relmada Therapeutics Inc (RLMD) has a Forward P/S ratio of 0.00. This means the market is valuing RLMD at $0.00 for every dollar of expected revenue over the next 12 months.

RLMD Valuation